ACP
SIOX

Acuta Capital Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Acuta Capital Partners’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-17,500
Closed -$1.81M – 71
2015
Q3 		$1.81M Sell
17,500
-3,750
-18% -$440K 1.05% 32
2015
Q2 		$3.46M Buy
+21,250
New +$3.6M 2.14% 14

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Acuta Capital Partners's SIOX Position: Q4 2015 in Review

Acuta Capital Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2015, closing a stake of 17,500 shares — an estimated $1.81M sold.

Acuta Capital Partners first reported a position in SIOX in Q2 2015 and held it in 2 quarters. The position peaked at $3.46M in Q2 2015. 70 funds tracked by Wall St. Rank hold SIOX as of Q4 2015.

  • Acuta Capital Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 17,500 Sio Gene Therapies Inc. Common Stock shares in Q4 2015, an estimated $1.81M.
  • Acuta Capital Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Acuta Capital Partners's Sio Gene Therapies Inc. Common Stock position peaked at $3.46M in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.